Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Lowers PT on Shire PLC on 2013 EPS

Share:
Related
Intercept Pharmaceuticals Soars 30%; Reuters Reported Company Exploring A Potential Sale
RBC Upgrades Shire To Outperform, Says Market Overestimating Competition
Intercept spikes 22% on sale rumors (Seeking Alpha)

In a report published Wednesday, Jefferies reiterated its Buy rating on Shire PLC (NASDAQ: SHPG), but lowered its price target from $117.00 to $112.00.

Jefferies noted, “We remain 3% shy of 2013E cons. EPS and Shire's +10% YoY aim, largely on more cautious sales notably AXR. Still this doesn't detract from our thesis that significant Phase II-III pipeline news this year should boost belief in long-term organic growth prospects. Near-term R&D spend can be justified whilst SG&A leverage delivers a robust +12% 2013-16E CAGR at a minimum, supporting a re-rating from the current paltry 13x 2014E.”

Shire PLC closed on Tuesday at $95.67.

Latest Ratings for SHPG

DateFirmActionFromTo
Feb 2016Guggenheim SecuritiesInitiates Coverage onNeutral
Feb 2016RBC CapitalUpgradesSector PerformOutperform
Jan 2016Exane BNP ParibasUpgradesNeutralOutperform

View More Analyst Ratings for SHPG
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (SHPG)

Get Benzinga's Newsletters